Pseudomyxoma Peritonei Therapy and Treatment
We're all 'veterans' of PMP treatment therapy!
What are my treatment options for Pseudomyxoma Peritonei?
Why do I need to be treated by a specialist?
Is surgery required as part of PMP therapy?
Will I need chemotherapy?
The obvious goal for any cancer therapy and treatment is to increase and improve your options for long term survival. Treatment with the best specialist, focused on attending to your specific diagnosis, may increase your opportunities for survival!
Pseudomyxoma Peritonei Therapy and Treatment Options
Although we share the same basic "diagnosis" each case is different from others and each patient is truly unique.
Your surgical oncologist will explain and review all treatment options for Pseudomyxoma Peritonei. Your treatment plan will depend on your overall health, the type of tumor (pathology), the quantity (mass) size and location of the tumor, and whether the cancer has metastasized.
Surgery
Treatment for the Pseudomyxoma Peritonei syndrome generally includes CRS or cytoreductive surgery with or without systemic chemotherapy and HIPEC.
The purpose of debulking surgery is to remove as much tumor as possible. Debulking surgery often includes the removal of the omentum and the right colon. Additionally, for women, debulking will likely include a hysterectomy, if this was not perfomed previously. Adhesions become more troublesome with any additional debulking surgeries.
Cytoreductive surgery is a detailed, lengthy procedure often requiring ten or more hours.
Tumors are removed and destroyed using a variety of surgical techniques including argon beam coagulator, electro-evaporation, laser, and ultrasonic dissection.
CRS (cytoreductive surgery) consists of the removal of as much mucin and visible tumor as possible, from the abdominal cavity. CRS surgery, refers to the removal of all visible tumors present throughout the peritoneal cavity. Cytoreductive Surgery includes thorough removal or destruction of all visible tumors throughout the surfaces of the peritoneum. Surgery may include the removal or resection of segments of small and large bowel, gall bladder, liver, omentum, ovaries, pancreas, spleen, stomach and uterus, and may require removing the lining of the peritoneum.
The goal of cytoreductive surgery is to eliminate all tumor and metastatic tissues from the abdominal cavity, in order to effectively deliver intra-peritoneal heated chemotherapy (HIPEC).
Cytoreductive Surgery or Cytoreduction (CRS) is performed under general anesthesia. CRS time averages eight to ten hours.
A longitudinal incision is made in the abdomen. The abdomen, pelvis and organs therein are carefully inspected, during which time all operable visible and palpable tumors and tumor deposits are removed. The peritoneum is stripped.
Following surgery patients are admitted to the intensive care unit (ICU) for 24 hours or longer, depending on the individual patient. Patients are then transferred to regular hospitalization for an average of two weeks. This time period will vary depending on the individual.
Hemicolectomy is a surgical procedure involving the removal of a portion of the colon next to the appendix. This procedure may also include the removal of nearby blood vessels and lymph nodes at the same time.
Peritonectomy refers to stripping the parietal peritoneum and resecting structures at the sites that contain adenomucinosis. A combination of surgical techniques are utilized including organ resection, when necessary and tumor destruction via electro-evaporation and argon beam coagulation.
CRS surgery for Appendix Cancer and Pseudomyxoma Peritonei may include the following:
Removal of the omentum, spleen and gall bladder,
Right hemicolectomy, colectomy, removal of the rectum and sigmoid,
Stripping tumor from the surface of the liver,
Resection of the pancreas,
Gastrectomy (partial or total removal of the stomach)
Stripping the peritoneum from left and right hemidiaphragm;
Pelvic peritonectomy,
Ileostomy,colostomy or urostomy
HIPEC is a chemotherapy treatment delivered directly into the peritoneal cavity, is treated as a separate topic on this website.
Hyperthermic intraperitoneal chemotherapy, or HIPEC, is a procedure in which heated chemotherapy is circulated within the abdomen. The chemotherapy(ies) (most commonly Mitomycin C or Mitomycin C plus Oxaliplatin) are heated to 42°C or 107.6°F with the goal of killing any hidden tumor cells. HIPEC includes the use of a heated sterile solution with chemotherapy continuously circulated throughout the abdominal cavity for approximately 90 minutes.
HIPEC treatment provides surgeons with the ability to apply high doses of chemotherapy directly into the peritoneal cavity without significant toxicity to the remainder of the body. The effects of heat with regionally applied chemotherapy, may increase the efficacy of the treatment, with the goal of achieving a cure. The HIPEC treatment is applied directly following peritonectomy or CRS (cytoreductive surgery.)
HIPEC is also referred to as perfusion. HIPEC involves perfusion of the peritoneal cavity.
HIPEC may be included at the conclusion of the cytoreductive surgery for the treatment of pseudomyxoma peritonei and appendix cancer if substantial tumor debulking is accomplished through CRS. HIPEC may be administered when complete removal of visible tumor (or debulking) is achieved through cytoreductive surgery; it involves perfusion of the peritoneal cavity with chemotherapy heated to approximately 40 degrees Celsius.
HIPEC is administered with the infusion of heated chemotherapy during the last 90 minutes of the CRS procedure. Through HIPEC the surgeon(s) intend to destroy any residual tumor cells that may not have been surgically removed during the actual CRS surgery process.
Although this procedure may initially sound drastic to the newly diagnosed patient, rarely is resection and/or removal of all of these organs is required. Each patient's case is unique and most patients live productive and healthy lives following surgery!
Refer to our surgeons and specialists page for an international listing of HIPEC treatment providers.
Where can I talk with other HIPEC patients?
Where can I find a HIPEC treatment specialist?
Systemic Chemotherapy
Once thought to be ineffective for the treatment of Pseudomyxoma Peritonei, cystemic chemotherapy treatment has become common during the past decade due to the development of several new colorectal cancer therapies. Several systemic chemotherapies have become treatment options for Appendix cancer and pseudomyxoma peritonei patients. Systemic chemotherapy targets cancer cells throughout the body and is delivered throughout the bloodstream.
The "Chemo Pals' Resource & Support Group"" is one of the largest, PMP Pal Resource Programs.
Participants in "Chemo Pals" are Pseudomyxoma Peritonei and Appendix Cancer patients who exchange information regarding the particular chemotherapy (ies) utilized, including results of their treatment regimens.
Is systemic chemotherapy an appropriate treatment for you?
International Listing of Pseudomyxoma Peritonei Treatment articles and abstracts
[Treatment of pseudomyxoma peritonei is developing]
Lepistö A, Osterlund P, Järvinen HJ.
Duodecim. 2010;126(14):1693-9. Finnish. PMID: 20804088 [PubMed - in process]Related citations
Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1290 patients.
Glehen O, Gilly FN, Boutitie F, Bereder JM, Quenet F, Sideris L, Mansvelt B, Lorimier G, Msika S, Elias D; the French Surgical Association.
Cancer. 2010 Aug 24. [Epub ahead of print]PMID: 20737573 [PubMed - as supplied by publisher]Related citations
Secondary Cytoreduction and Perioperative Intraperitoneal Chemotherapy after Initial Debulking of Pseudomyxoma Peritonei: A Study of Timing and the Impact of Malignant Dedifferentiation.
Chua TC, Al-Zahrani A, Saxena A, Liauw W, Zhao J, Morris DL.
J Am Coll Surg. 2010 Aug 20. [Epub ahead of print]PMID: 20729102 [PubMed - as supplied by publisher]Related citations
[Prospective study of quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy using oxaliplatin for peritoneal carcinomatosis.]
Lim C, Tordjmann D, Gornet JM, Nemeth J, Valleur P, Pocard M.
Bull Cancer. 2010 Aug 6. [Epub ahead of print] French. PMID: 20693116 [PubMed - as supplied by publisher]Related citations
Primary peritonectomy/HIPEC for disseminated peritoneal adenomucinosis achieves much lower recurrence rates and better survival than secondary procedures.
Zhu KJ, Morris DL.
Surgeon. 2009 Dec;7(6):345-50.PMID: 20681377 [PubMed - indexed for MEDLINE]Related citations
Mucinous adenocarcinomas with intra-abdominal dissemination: a review of current therapy.
Winder T, Lenz HJ.
Oncologist. 2010;15(8):836-44. Epub 2010 Jul 23.PMID: 20656916 [PubMed - in process]Related citations
[Prognostic factors and reproductive outcomes of borderline ovarian tumors: a review of 186 patients]
Tao T, Cao DY, Yang JX, Huang HF, Wu M, Pan LY, Lang JH, Guo LN, Shen K.
Zhonghua Yi Xue Za Zhi. 2010 May 18;90(19):1304-8. Chinese. PMID: 20646576 [PubMed - indexed for MEDLINE]Related citations
Case records of the Massachusetts General Hospital. Case 19-2010. A 35-year-old man with adenocarcinoma of the cecum.
Ryan DP, Engelman JA, Ferrone CR, Sahani DV, Lisovsky M.
N Engl J Med. 2010 Jun 24;362(25):2411-9. No abstract available. PMID: 20573930 [PubMed - indexed for MEDLINE]Related citations
Mesenteric cyst: report of a case-resulting in pseudomyxoma peritonei.
Zappa L, Sugarbaker PH.
Tumori. 2010 Mar-Apr;96(2):332-5.PMID: 20572595 [PubMed - indexed for MEDLINE]Related citations
[Peritoneal carcinosis can have as good a prognosis as primary colonic cancer, and should be managed according to evidence-based practice]
Graf W, Mahteme H.
Lakartidningen. 2010 May 12-25;107(19-20):1320. Swedish. No abstract available. PMID: 20556987 [PubMed - indexed for MEDLINE]Related citations
Alpha Index of Pseudomyxoma Peritonei Treatment Articles by PMP Cancer Specialists
We provide the following abstracts, articles and videos, published by, and/or written about the world's most experienced specialists in the treatment and research of Pseudomyxoma Peritonei ,Peritoneal Carcinomatosis, Mesothelioma and Appendix Cancer. The full titles of some abstracts have been abbreviated due to space limitations.
Articles by Dr SA Ahrendt, USA
CRS and HIPEC for Treatment of Peritoneal Carcinomatosis in Colorectal Cancer Patient with Liver Metastasis: Study of 57 Patients
Source: Journal of Clinical Oncology 2008
CRS and HIPEC for Treatment of Peritoneal Carcinomatosis
Source: Annals of Surgical Oncology, 2008
CRS and HIPEC for Treatment of Colorectal Carcinomatosis
Source: Annals of Surgial Oncology, Nov 2008
Articles by Dr Fernando Arias, Colombia
Sleeve Gastrectomy
Source: Fundacion Santa Fe de Bogota
Abstracts by Dr Mario Baratti, Italy
Pseudomyxoma Peritonei Biological Features Are the Dominant Prognostic Determinants After Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy
Source: Annals of Surgery, Dr Marcello Deraco, Dr Baratti, 2009
Articles by Dr David L Bartlett, USA
CRS and HIPEC for Treatment of Peritoneal Carcinomatosis in Colorectal Cancer Patient with Liver Metastasis: Study of 57 Patients
Source: Journal of Clinical Oncology 2008
CRS and HIPEC for Treatment of Peritoneal Carcinomatosis
Source: Anuals of Surgical Oncology, 2008
HIPEC: The Complexity of Clinical Trials
Source: Dr David L Bartlett, UPMC, Society of Surgical Oncology 2008
Dr David L Bartlett, Dr James Pingpank, Dr Steven Ahrendt
Source: Koch Cancer Treatment Center, UPMC
Profile for Dr David L Bartlett
Source: UPMC
Dr David L Bartlett: Koch Cancer Center
Source: UPMC
Dr David L Bartlett: Treatment of Liver Cancer
Source: UPMC Koch Cancer Center
Articles by Dr Jean Bereder, France
Study of 300+ Patients Treated with CRS and PIC
Abstract of a study of 300+ Pseudomyxoma Peritonei patients treated with cytoreductive surgery and intraperitoneal chemotherapy. Describes "gold standard " of treatment.
Source: Elias D, Gilly F, Quenet F, Bereder JM, Sidéris L, Mansvelt B, Lorimier G, Glehen O; the Association Française de Chirurgie.
Department of Oncologic Surgery, Institut Gustave Roussy, 39 Rue Camille Desmoulins, 94805 Villejuif Cédex, France March 2010
Study of 523 Colorectal Peritoneal Carcinomatosis Cases: CRS and IPC
Source: Journal of Clinical Oncology,2010
Articles by Dr Wim Ceelen, Belgium
Dr Wim P Ceelen treats Pseudomyxoma Peritonei with HIPEC www.surgery.ugent.be
Articles by Dr Marcello Deraco, Italy
Pseudomyxoma PeritoneiBiological Features Are the Dominant Prognostic Determinants After Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy
Source: Annals of Surgery, Dr Marcello Deraco, Dr Baratti, 2009
HIPEC Treatment: Dott. Marcello Deraco: Pseudomyxoma Peritonei and Appendix Cancer
Source: Dott. Marcello Deraco
Articles by Dr D Elias, France
Study of 523 Colorectal Peritoneal Carcinomatosis Cases: CRS and IPC
Source: Journal of Clinical Oncology,2010
Articles by Dr Jesus Esquivel, USA
Learning Curve for CRS and HIPEC
Source: Journal of Surgical Oncology, August 2009
Laparoscopic CRS and HIPEC Treatment for Peritoneal Mesothelioma
Source: Dr Jesus Esquivel, 2009
HIPEC Treatment available at St Agnes Hospital
Source: Dr Jesus Esquivel
Pros and Cons of HIPEC: Dr Jesus Esquivel
Source: Oncology Times, Jan 2007
Physician Profile for Dr Jesus Esquivel
Source: St Agnes Hospital
Dr Jesus Esquivel:St Agnes Hospital
Source: St Agnes Hospital
Articles by Dr Jan Franko, USA
CRS and HIPEC for Treatment of Peritoneal Carcinomatosis in Colorectal Cancer Patient with Liver Metastasis: Study of 57 Patients
Source: Journal of Clinical Oncology 2008
CRS and HIPEC for Treatment of Peritoneal Carcinomatosis
Source: Annals of Surgical Oncology, 2008
CRS and HIPEC for Treatment of Colorectal Carcinomatosis
Source: Annals of Surgial Oncology, Nov 2008
Click here to read Dr Jan Franko's profile
Source: Mercy Medical Center
Articles by Dr Gilly, France
Study of 300+ Patients Treated with CRS and PIC :
Abstract of a study of 300+ Pseudomyxoma Peritonei patients treated with cytoreductive surgery and intraperitoneal chemotherapy. Describes "gold standard " of treatment.
Source: Elias D, Gilly F, Quenet F, Bereder JM, Sidéris L, Mansvelt B, Lorimier G, Glehen O; the Association Française de Chirurgie.
Department of Oncologic Surgery, Institut Gustave Roussy, 39 Rue Camille Desmoulins, 94805 Villejuif Cédex, France March 2010
Study of 523 Colorectal Peritoneal Carcinomatosis Cases: CRS and IPC
Source: Journal of Clinical Oncology,2010
Articles by Dr Matthew Holtzman, USA
CRS and HIPEC for Treatment of Peritoneal Carcinomatosis in Colorectal Cancer Patient with Liver Metastasis: Study of 57 Patients
Source: Journal of Clinical Oncology 2008
Articles by Dr Joachim Jahne, Germany
CRS:Stategies to Reduce Post Op Morbidity and Complications
Source: Dr Joachim Jahne, April 2009
Articles by Dr Santiago Gonzalez-Moreno, Spain
Patient Selection for CRS and HIPEC
Source: Journal of Surgical Oncology 2009
Articles by Dr Martin Goodman, USA
Dr Martin Goodman at Tufts University provides HIPEC
Source: Tufts University, Boston
Articles by Dr Matthew Holtzman, USA
CRS and HIPEC for Treatment of Peritoneal Carcinomatosis
Source: Annals of Surgical Oncology, 2008
CRS and HIPEC for Treatment of Colorectal Carcinomatosis
Source: Annals of Surgial Oncology, Nov 2008
Articles by Dr Laura Lambert, USA
CRS and Perioperative Intraperitoneal Chemotherapy for Colorectal Carcinomatosis:
Source: Annals of Surgical Oncology. 2007, Lambert, Laura A. and Paul F. Mansfield.
See: http://www.annalssurgicaloncology.org/cgi/content/full/14/11/3037
Articles by Dr Edward Levine, USA
CRS and HIPEC for the Treatment of Peritoneal Dissemination of Appendiceal and Colorectal Neoplasms
Source: Dr Edward Levine, ASCO 2008
“Appendiceal Carcinoma with Peritoneal Dissemination: Outcomes for the Best of the Best.”
Source: Annals of Surgical Oncology,2007, Dr Edward Levine, WFU
Survival Study for Pseudomyxoma Peritonei: DPAM, PMCA, PMCA 1
Source: Dr Edward Levine, American Journal of Surgical Pathology, May 2006
DPAM and HIPEC Treatment
Source: Wake Forest University
Articles by Dr Brian W Loggie, USA
CRS with HIPEC have improved quality and quantity of life for patients
Source:Dr Brian Loggie, 2007
Cox II expression in patients with Pseudomyxoma Peritonei and Disseminated Peritoneal Adenomucinosis
Source: Dr Brian Loggie
Articles referring to Dr Brian Loggie's patients
Source: PMP Pals' Network
Articles by Dr Andrew Lowy, USA
Minimally Invasive Laparoscopic Treatment of Pseudomyxoma Peritonei
Source: UCSD, Dr Andrew Lowy, 2009
Dr Andrew Lowy:Moores Cancer Center
Source: UCSD
Treatment of Pancreatic Cancer
Source: Dr Andrew Lowy UCSD
Articles by Dr Paul Mansfield, USA
Profile for Dr Paul Mansfield
Source: MD Anderson
CRS and HIPEC for the Treatment of Peritoneal Dissemination of Appendiceal and Colorectal Neoplasms
Source: Dr Paul Mansfield, ASCO 2008
CRS and Perioperative Intraperitoneal Chemotherapy for Colorectal Carcinomatosis:
Source: Annals of Surgical Oncology. 2007, Lambert, Laura A. and Paul F. Mansfield.
See: http://www.annalssurgicaloncology.org/cgi/content/full/14/11/3037
Laparoscopic Staging for Gastric Cancer
Source: Dr Paul Mansfield, MDACC, Annals of Surgical Oncology, 2001
Laparoscopy for Surgical Oncology
Source: MDACC
Articles by Dr Brendan J Moran, United Kingdom
CRS and HIPEC for the Treatment of Patients age 30-77 years
Source: North Hampshire Hospital, Basingstoke UK, 2007
Articles by Prof David L Morris, Australia
Radiofrequency Ablation for Treatment of Unresectable Colorectal Pulmonary Metastes
Radiofrequency ablation as an adjunct to systemic chemotherapy for colorectal pulmonary metastases. Radiofrequency ablation for colorectal pulmonary metastases represents a step forward towards a nonsurgical option of combining systemic and local treatment for metastatic disease and is a safe treatment with a low risk profile.
Source: David L. Morris, MD, PhD 2009
Morbidity and Mortality: Study of HIPEC and CRS for Treatment of Peritoneal Carcinomatosis
Source: Annals of Surgery, Feb 2009, Dr David Morris, Dr Tristan Yan
DPAM: Peritonectomy Improves Survival
Source Prof David L Morris, 2009
Assessment of risk factors following CRS and chemotherapy
Source: Dr David L Morris, Dr Tristan Yan, 2009Cost effectiveness of treatment with CRS and HIPEC
Source: Dr David L Morris, Dr Tristan Yan, Dec 2009
Pseudomyxoma Peritonei Long Term Survival (10 year study)
Source: Annals of Surgical Oncology, 2009, Prof David L Morris, St George Hospital,Univ of New South Wales, Sydney, NSW, AU
Long-term survival in patients with pseudomyxoma peritonei treated with cytoreductive surgery and perioperative intraperitoneal chemotherapy: 10 years of experience.
This report demonstrates long-term survival outcomes, acceptable perioperative outcomes, and a learning curve associated with the treatment of patients with pseudomyxoma peritonei.
In vivo model for Pseudomyxoma Peritonei research
Source: Prof David L Morris, Sydney Australia, 2009
Articles by Dr Stefaan Mulier, Belgium
Dr Stefaan Mulier provides HIPEC treatment for Pseudomyxoma Peritonei and Peritoneal Carcinomatosis
Source: Leopold Park Clinic in Brussels
Articles by Dr Herwart Mueller, Germany
CRS for Senior Patients
Source: Dr Herwart Mueller, Germany
Articles by Dr Garrett M Nash USA
Laparoscopic Surgery for the Treatment of Peritoneal Surface Malignancies including Pseudomyxoma Peritonei
Source: Memorial Sloan Kettering, NY
Articles by Dr Haydee Ojeda-Fournier, USA
Diagnostic Imaging of Pancreatic Cancer
Source: Dr Haydee Ojeda-Fournier, UCSD
Articles by Dr Gloria Ortega-Perez, Spain
Patient Selection for CRS and HIPEC
Source: Journal of Surgical Oncology 2009
Articles by Dr James Pingpank, USA
Peritoneal Carcinomatois Clinical Trials Study
Source: NIH, Dr James Pingpank, Feb 2009
Articles by Prof Pompiliu Piso, Germany
Peritoneal Carcinomatosis Treatment (Study) with Tumor Honing Peptides
Source: Dept of Radiology, Germany 2009
Peritoneal Carcinomatosis Prognosis following treatment with surgery and HIPEC
Source: Prof P Piso, 2009
CRS and HIPEC for the Treatment of Peritoneal Carcinomatosis
Source: Prof Pompiliu Piso, 3rd Annual Symposium, 2008
HIPEC Study with laboratory rats
Source: Deutscher Krebskongress, 2004
Articles by Dr B Ronnett, USA
CRS and HIPEC for the Treatment of Peritoneal Dissemination of Appendiceal and Colorectal Neoplasms
Source: Dr Edward Levine, ASCO 2008
DPAM Long Term Survival
Source: Dr BM Ronnett, Dr Paul H Sugarbaker, 2009
Articles by Dr Armando Sardi, USA
CRS and HIPEC offer longterm survival for Peritoneal Carcinomatosis of disseminated Appendiceal tumor origin
Source: Dr Armando Sardi, Mercy Med Center, Journal of American College of Surgeons, Sept 2009
Published abstracts by Dr Armando Sardi
Source: Mercy Medical Center
Steps to Prepare for SurgerySource: Mercy Medical Center
Curriculum Vitae for Dr Armando Sardi
Source: Mercy Medical Center
Profile for Dr Armando Sardi
Source: Mercy Medical Center
Articles by Dr Perry Shen, USA
Dr Perry Shen at WFU provides HIPEC
Source: Wake Forest University
Articles by Dr Paul H Sugarbaker, USA
Surgical Responsibilities in the Management of Peritoneal Carcinomatosis
Source: Dr Paul H Sugarbaker, June 2010, Pub Med
Mesenteric Cyst resulting in Pseudomyxoma Peritonei
Source: Dr Paul H Sugarbaker, 2010
Tailgut Cyst: An Unusual Case of Pseudomyxoma Peritonei
Source: Tumori, Dr Paul H Sugarbaker, 2009
Epithelial appendiceal neoplasms (abstract with availability to purchase article in full)
Source: The Cancer Journal, 2009
Epithelial appendiceal neoplasms: report reviews 900 cases treated at the Washington Hospital Center
Source: Dr Paul H Sugarbaker, Cancer Journal, May 2009
DPAM Long Term Survival
Source: Dr BM Ronnett, Dr Paul H Sugarbaker, 2009
Management of mucinous urachal neoplasm presenting as Pseudomyxoma Peritonei
Source: Dr Paul H Sugarbaker, 2008
Failure Analysis of Recurrent Disease Following CRS and IPC for Colorectal Cancer with Peritoneal Carcinomatosis
Source: Dr Paul H Sugarbaker, Dr Tristan Yan, 2007
Treatment of Peritoneal Surface Malignancy
Source: Dr Paul H Sugarbaker, Dr Tristan Yan, Journal of Transistional Medicine, 2006
Cytoreductive Surgery (includes graphic illustrations) Source: Dr Paul H Sugarbaker
Indications for use of CRS and HIPEC
Source: Dr Paul H Sugarbaker
Appendix Cancer Prognosis
Source: Dr Paul H Sugarbaker, Washington Hospital Center
Prognostic indicators for Peritoneal Carcinomatosis originating with gastrointestinal adenocarcinoma
Source: Dr Paul H Sugarbaker, 2005
Atlas of Appendix Cancer(includes graphic illustrations)
Source: Dr Paul H Sugarbaker
Articles referring to Dr Paul Sugarbaker and his patients
Source: PMP Pals' Network
Articles by Dr V J Verwaal,Holland
Population Based Study of Appendiceal Neoplasms and Pseudomyxoma Peritonei
Source: ESJO, 2008
Cytoreduction and HIPEC Treatment for Appendix Cancer and Pseudomyxoma Peritonei (pdf)
Source: Netherlands Cancer Institute, Prof VJ Verwaal, 2006
Articles by Dr Tristan Yan, Australia
Cost effectiveness of treatment with CRS and HIPEC
Source: Dr David L Morris, Dr Tristan Yan, Dec 2009
Morbidity and Mortality: Study of HIPEC and CRS for Treatment of Peritoneal Carcinomatosis
Source: Annals of Surgery, Feb 2009, Dr David Morris, Dr Tristan Yan
Assessment of risk factors following CRS and chemotherapy
Source: Dr David L Morris, Dr Tristan Yan, 2009
Failure Analysis of Recurrent Disease Following CRS and IPC for Colorectal Cancer with Peritoneal Carcinomatosis
Source: Dr Paul H Sugarbaker, Dr Tristan Yan, 2007
Treatment of Peritoneal Surface Malignancy
Source: Dr Paul H Sugarbaker, Dr Tristan Yan, Journal of Transistional Medicine, 2006
Articles by Dr H Zeh, USA
CRS and HIPEC for Treatment of Peritoneal Carcinomatosis in Colorectal Cancer Patient with Liver Metastasis: Study of 57 Patients
Source: Journal of Clinical Oncology 2008
CRS and HIPEC for Treatment of Peritoneal Carcinomatosis
Source: Annals of Surgical Oncology, 2008
CRS and HIPEC for Treatment of Colorectal Carcinomatosis
Source: Annals of Surgial Oncology, Nov 2008
Articles by Dr F Zoetmulder, Holland
Population Based Study of Appendiceal Neoplasms and Pseudomyxoma Peritonei
Source: ESJO, 2008
Prospective longitudinal study of quality of life following cytoreductive surgery and intraperitoneal chemotherapy for Pseudomyxoma Peritonei.
Submitted by Alves S, Mohamed F, Yadegarfar G, Youssef H, Moran BJ. Pseudomyxoma Peritonei Centre, Basingstoke and North Hampshire Hospital Foundation Trust, Aldermaston Road, Basingstoke, Hampshire RG24 9NA, UK.
Abstract
BACKGROUND: Pseudomyxoma peritonei (PMP) is characterized by mucinous ascites, predominantly arising form a perforated tumour of the appendix. This study aimed to assess Health-Related Quality of Life (HRQL) in patients following cytoreductive surgery and intraperitoneal chemotherapy for PMP.
METHODS: Over a one year period, 49 consecutive patients (13 male, 36 females) with a median age of 55 (range 37-81 years) were enrolled. Patients were asked to complete the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 questionnaire prior to surgery and at one, three, six and twelve months post-operatively.
RESULTS: 26 patients (53%) underwent complete cytoreduction and 20 (42%) patients had major tumour debulking. One patient died from progressive disease three months from surgery and two patients withdrew from the study within 6 months of surgery. Baseline questionnaire compliance was 100 per cent and remained high (overall 98% of eligible patients) during follow up. Grade III/IV morbidity occurred in 4 patients (9%). Patients undergoing both complete cytoreduction and major tumour debulking reported a clinically significant improvement in emotional well-being, appetite and global HRQL at 1 year following surgery.
CONCLUSION: Despite the high morbidity associated with cytoreductive surgery and intraperitoneal chemotherapy, an improvement in quality of life at 1 year following the procedure was seen following both complete cytoreduction and major tumour debulking. Longer term assessment is required to demonstrate the durability of this enhancement.
SOURCE: Eur J Surg Oncol. 2010 Sep 21.
Pseudomyxoma Peritonei Treatment Resources
How can I learn more about "PMP?"
Can I talk directly with other patients and their families?
To begin seeking resources for the treatment of Pseudomyxoma Peritonei, and related diseases, patients should obtain a copy of one's own pathology report to read how your particular case has been identified.
Join the PMP Pals' Network and begin communicating with other patients and their families today!
Why do I need to be treated by a specialist?
Is surgery required as part of PMP therapy?
Will I need chemotherapy?
The obvious goal for any cancer therapy and treatment is to increase and improve your options for long term survival. Treatment with the best specialist, focused on attending to your specific diagnosis, may increase your opportunities for survival!
Pseudomyxoma Peritonei Therapy and Treatment Options
Although we share the same basic "diagnosis" each case is different from others and each patient is truly unique.
Your surgical oncologist will explain and review all treatment options for Pseudomyxoma Peritonei. Your treatment plan will depend on your overall health, the type of tumor (pathology), the quantity (mass) size and location of the tumor, and whether the cancer has metastasized.
Surgery
Treatment for the Pseudomyxoma Peritonei syndrome generally includes CRS or cytoreductive surgery with or without systemic chemotherapy and HIPEC.
The purpose of debulking surgery is to remove as much tumor as possible. Debulking surgery often includes the removal of the omentum and the right colon. Additionally, for women, debulking will likely include a hysterectomy, if this was not perfomed previously. Adhesions become more troublesome with any additional debulking surgeries.
Cytoreductive surgery is a detailed, lengthy procedure often requiring ten or more hours.
Tumors are removed and destroyed using a variety of surgical techniques including argon beam coagulator, electro-evaporation, laser, and ultrasonic dissection.
CRS (cytoreductive surgery) consists of the removal of as much mucin and visible tumor as possible, from the abdominal cavity. CRS surgery, refers to the removal of all visible tumors present throughout the peritoneal cavity. Cytoreductive Surgery includes thorough removal or destruction of all visible tumors throughout the surfaces of the peritoneum. Surgery may include the removal or resection of segments of small and large bowel, gall bladder, liver, omentum, ovaries, pancreas, spleen, stomach and uterus, and may require removing the lining of the peritoneum.
The goal of cytoreductive surgery is to eliminate all tumor and metastatic tissues from the abdominal cavity, in order to effectively deliver intra-peritoneal heated chemotherapy (HIPEC).
Cytoreductive Surgery or Cytoreduction (CRS) is performed under general anesthesia. CRS time averages eight to ten hours.
A longitudinal incision is made in the abdomen. The abdomen, pelvis and organs therein are carefully inspected, during which time all operable visible and palpable tumors and tumor deposits are removed. The peritoneum is stripped.
Following surgery patients are admitted to the intensive care unit (ICU) for 24 hours or longer, depending on the individual patient. Patients are then transferred to regular hospitalization for an average of two weeks. This time period will vary depending on the individual.
Hemicolectomy is a surgical procedure involving the removal of a portion of the colon next to the appendix. This procedure may also include the removal of nearby blood vessels and lymph nodes at the same time.
Peritonectomy refers to stripping the parietal peritoneum and resecting structures at the sites that contain adenomucinosis. A combination of surgical techniques are utilized including organ resection, when necessary and tumor destruction via electro-evaporation and argon beam coagulation.
CRS surgery for Appendix Cancer and Pseudomyxoma Peritonei may include the following:
Removal of the omentum, spleen and gall bladder,
Right hemicolectomy, colectomy, removal of the rectum and sigmoid,
Stripping tumor from the surface of the liver,
Resection of the pancreas,
Gastrectomy (partial or total removal of the stomach)
Stripping the peritoneum from left and right hemidiaphragm;
Pelvic peritonectomy,
Ileostomy,colostomy or urostomy
HIPEC is a chemotherapy treatment delivered directly into the peritoneal cavity, is treated as a separate topic on this website.
Hyperthermic intraperitoneal chemotherapy, or HIPEC, is a procedure in which heated chemotherapy is circulated within the abdomen. The chemotherapy(ies) (most commonly Mitomycin C or Mitomycin C plus Oxaliplatin) are heated to 42°C or 107.6°F with the goal of killing any hidden tumor cells. HIPEC includes the use of a heated sterile solution with chemotherapy continuously circulated throughout the abdominal cavity for approximately 90 minutes.
HIPEC treatment provides surgeons with the ability to apply high doses of chemotherapy directly into the peritoneal cavity without significant toxicity to the remainder of the body. The effects of heat with regionally applied chemotherapy, may increase the efficacy of the treatment, with the goal of achieving a cure. The HIPEC treatment is applied directly following peritonectomy or CRS (cytoreductive surgery.)
HIPEC is also referred to as perfusion. HIPEC involves perfusion of the peritoneal cavity.
HIPEC may be included at the conclusion of the cytoreductive surgery for the treatment of pseudomyxoma peritonei and appendix cancer if substantial tumor debulking is accomplished through CRS. HIPEC may be administered when complete removal of visible tumor (or debulking) is achieved through cytoreductive surgery; it involves perfusion of the peritoneal cavity with chemotherapy heated to approximately 40 degrees Celsius.
HIPEC is administered with the infusion of heated chemotherapy during the last 90 minutes of the CRS procedure. Through HIPEC the surgeon(s) intend to destroy any residual tumor cells that may not have been surgically removed during the actual CRS surgery process.
Although this procedure may initially sound drastic to the newly diagnosed patient, rarely is resection and/or removal of all of these organs is required. Each patient's case is unique and most patients live productive and healthy lives following surgery!
Refer to our surgeons and specialists page for an international listing of HIPEC treatment providers.
Where can I talk with other HIPEC patients?
Where can I find a HIPEC treatment specialist?
Systemic Chemotherapy
Once thought to be ineffective for the treatment of Pseudomyxoma Peritonei, cystemic chemotherapy treatment has become common during the past decade due to the development of several new colorectal cancer therapies. Several systemic chemotherapies have become treatment options for Appendix cancer and pseudomyxoma peritonei patients. Systemic chemotherapy targets cancer cells throughout the body and is delivered throughout the bloodstream.
The "Chemo Pals' Resource & Support Group"" is one of the largest, PMP Pal Resource Programs.
Participants in "Chemo Pals" are Pseudomyxoma Peritonei and Appendix Cancer patients who exchange information regarding the particular chemotherapy (ies) utilized, including results of their treatment regimens.
Is systemic chemotherapy an appropriate treatment for you?
International Listing of Pseudomyxoma Peritonei Treatment articles and abstracts
[Treatment of pseudomyxoma peritonei is developing]
Lepistö A, Osterlund P, Järvinen HJ.
Duodecim. 2010;126(14):1693-9. Finnish. PMID: 20804088 [PubMed - in process]Related citations
Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1290 patients.
Glehen O, Gilly FN, Boutitie F, Bereder JM, Quenet F, Sideris L, Mansvelt B, Lorimier G, Msika S, Elias D; the French Surgical Association.
Cancer. 2010 Aug 24. [Epub ahead of print]PMID: 20737573 [PubMed - as supplied by publisher]Related citations
Secondary Cytoreduction and Perioperative Intraperitoneal Chemotherapy after Initial Debulking of Pseudomyxoma Peritonei: A Study of Timing and the Impact of Malignant Dedifferentiation.
Chua TC, Al-Zahrani A, Saxena A, Liauw W, Zhao J, Morris DL.
J Am Coll Surg. 2010 Aug 20. [Epub ahead of print]PMID: 20729102 [PubMed - as supplied by publisher]Related citations
[Prospective study of quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy using oxaliplatin for peritoneal carcinomatosis.]
Lim C, Tordjmann D, Gornet JM, Nemeth J, Valleur P, Pocard M.
Bull Cancer. 2010 Aug 6. [Epub ahead of print] French. PMID: 20693116 [PubMed - as supplied by publisher]Related citations
Primary peritonectomy/HIPEC for disseminated peritoneal adenomucinosis achieves much lower recurrence rates and better survival than secondary procedures.
Zhu KJ, Morris DL.
Surgeon. 2009 Dec;7(6):345-50.PMID: 20681377 [PubMed - indexed for MEDLINE]Related citations
Mucinous adenocarcinomas with intra-abdominal dissemination: a review of current therapy.
Winder T, Lenz HJ.
Oncologist. 2010;15(8):836-44. Epub 2010 Jul 23.PMID: 20656916 [PubMed - in process]Related citations
[Prognostic factors and reproductive outcomes of borderline ovarian tumors: a review of 186 patients]
Tao T, Cao DY, Yang JX, Huang HF, Wu M, Pan LY, Lang JH, Guo LN, Shen K.
Zhonghua Yi Xue Za Zhi. 2010 May 18;90(19):1304-8. Chinese. PMID: 20646576 [PubMed - indexed for MEDLINE]Related citations
Case records of the Massachusetts General Hospital. Case 19-2010. A 35-year-old man with adenocarcinoma of the cecum.
Ryan DP, Engelman JA, Ferrone CR, Sahani DV, Lisovsky M.
N Engl J Med. 2010 Jun 24;362(25):2411-9. No abstract available. PMID: 20573930 [PubMed - indexed for MEDLINE]Related citations
Mesenteric cyst: report of a case-resulting in pseudomyxoma peritonei.
Zappa L, Sugarbaker PH.
Tumori. 2010 Mar-Apr;96(2):332-5.PMID: 20572595 [PubMed - indexed for MEDLINE]Related citations
[Peritoneal carcinosis can have as good a prognosis as primary colonic cancer, and should be managed according to evidence-based practice]
Graf W, Mahteme H.
Lakartidningen. 2010 May 12-25;107(19-20):1320. Swedish. No abstract available. PMID: 20556987 [PubMed - indexed for MEDLINE]Related citations
Alpha Index of Pseudomyxoma Peritonei Treatment Articles by PMP Cancer Specialists
We provide the following abstracts, articles and videos, published by, and/or written about the world's most experienced specialists in the treatment and research of Pseudomyxoma Peritonei ,Peritoneal Carcinomatosis, Mesothelioma and Appendix Cancer. The full titles of some abstracts have been abbreviated due to space limitations.
Articles by Dr SA Ahrendt, USA
CRS and HIPEC for Treatment of Peritoneal Carcinomatosis in Colorectal Cancer Patient with Liver Metastasis: Study of 57 Patients
Source: Journal of Clinical Oncology 2008
CRS and HIPEC for Treatment of Peritoneal Carcinomatosis
Source: Annals of Surgical Oncology, 2008
CRS and HIPEC for Treatment of Colorectal Carcinomatosis
Source: Annals of Surgial Oncology, Nov 2008
Articles by Dr Fernando Arias, Colombia
Sleeve Gastrectomy
Source: Fundacion Santa Fe de Bogota
Abstracts by Dr Mario Baratti, Italy
Pseudomyxoma Peritonei Biological Features Are the Dominant Prognostic Determinants After Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy
Source: Annals of Surgery, Dr Marcello Deraco, Dr Baratti, 2009
Articles by Dr David L Bartlett, USA
CRS and HIPEC for Treatment of Peritoneal Carcinomatosis in Colorectal Cancer Patient with Liver Metastasis: Study of 57 Patients
Source: Journal of Clinical Oncology 2008
CRS and HIPEC for Treatment of Peritoneal Carcinomatosis
Source: Anuals of Surgical Oncology, 2008
HIPEC: The Complexity of Clinical Trials
Source: Dr David L Bartlett, UPMC, Society of Surgical Oncology 2008
Dr David L Bartlett, Dr James Pingpank, Dr Steven Ahrendt
Source: Koch Cancer Treatment Center, UPMC
Profile for Dr David L Bartlett
Source: UPMC
Dr David L Bartlett: Koch Cancer Center
Source: UPMC
Dr David L Bartlett: Treatment of Liver Cancer
Source: UPMC Koch Cancer Center
Articles by Dr Jean Bereder, France
Study of 300+ Patients Treated with CRS and PIC
Abstract of a study of 300+ Pseudomyxoma Peritonei patients treated with cytoreductive surgery and intraperitoneal chemotherapy. Describes "gold standard " of treatment.
Source: Elias D, Gilly F, Quenet F, Bereder JM, Sidéris L, Mansvelt B, Lorimier G, Glehen O; the Association Française de Chirurgie.
Department of Oncologic Surgery, Institut Gustave Roussy, 39 Rue Camille Desmoulins, 94805 Villejuif Cédex, France March 2010
Study of 523 Colorectal Peritoneal Carcinomatosis Cases: CRS and IPC
Source: Journal of Clinical Oncology,2010
Articles by Dr Wim Ceelen, Belgium
Dr Wim P Ceelen treats Pseudomyxoma Peritonei with HIPEC www.surgery.ugent.be
Articles by Dr Marcello Deraco, Italy
Pseudomyxoma PeritoneiBiological Features Are the Dominant Prognostic Determinants After Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy
Source: Annals of Surgery, Dr Marcello Deraco, Dr Baratti, 2009
HIPEC Treatment: Dott. Marcello Deraco: Pseudomyxoma Peritonei and Appendix Cancer
Source: Dott. Marcello Deraco
Articles by Dr D Elias, France
Study of 523 Colorectal Peritoneal Carcinomatosis Cases: CRS and IPC
Source: Journal of Clinical Oncology,2010
Articles by Dr Jesus Esquivel, USA
Learning Curve for CRS and HIPEC
Source: Journal of Surgical Oncology, August 2009
Laparoscopic CRS and HIPEC Treatment for Peritoneal Mesothelioma
Source: Dr Jesus Esquivel, 2009
HIPEC Treatment available at St Agnes Hospital
Source: Dr Jesus Esquivel
Pros and Cons of HIPEC: Dr Jesus Esquivel
Source: Oncology Times, Jan 2007
Physician Profile for Dr Jesus Esquivel
Source: St Agnes Hospital
Dr Jesus Esquivel:St Agnes Hospital
Source: St Agnes Hospital
Articles by Dr Jan Franko, USA
CRS and HIPEC for Treatment of Peritoneal Carcinomatosis in Colorectal Cancer Patient with Liver Metastasis: Study of 57 Patients
Source: Journal of Clinical Oncology 2008
CRS and HIPEC for Treatment of Peritoneal Carcinomatosis
Source: Annals of Surgical Oncology, 2008
CRS and HIPEC for Treatment of Colorectal Carcinomatosis
Source: Annals of Surgial Oncology, Nov 2008
Click here to read Dr Jan Franko's profile
Source: Mercy Medical Center
Articles by Dr Gilly, France
Study of 300+ Patients Treated with CRS and PIC :
Abstract of a study of 300+ Pseudomyxoma Peritonei patients treated with cytoreductive surgery and intraperitoneal chemotherapy. Describes "gold standard " of treatment.
Source: Elias D, Gilly F, Quenet F, Bereder JM, Sidéris L, Mansvelt B, Lorimier G, Glehen O; the Association Française de Chirurgie.
Department of Oncologic Surgery, Institut Gustave Roussy, 39 Rue Camille Desmoulins, 94805 Villejuif Cédex, France March 2010
Study of 523 Colorectal Peritoneal Carcinomatosis Cases: CRS and IPC
Source: Journal of Clinical Oncology,2010
Articles by Dr Matthew Holtzman, USA
CRS and HIPEC for Treatment of Peritoneal Carcinomatosis in Colorectal Cancer Patient with Liver Metastasis: Study of 57 Patients
Source: Journal of Clinical Oncology 2008
Articles by Dr Joachim Jahne, Germany
CRS:Stategies to Reduce Post Op Morbidity and Complications
Source: Dr Joachim Jahne, April 2009
Articles by Dr Santiago Gonzalez-Moreno, Spain
Patient Selection for CRS and HIPEC
Source: Journal of Surgical Oncology 2009
Articles by Dr Martin Goodman, USA
Dr Martin Goodman at Tufts University provides HIPEC
Source: Tufts University, Boston
Articles by Dr Matthew Holtzman, USA
CRS and HIPEC for Treatment of Peritoneal Carcinomatosis
Source: Annals of Surgical Oncology, 2008
CRS and HIPEC for Treatment of Colorectal Carcinomatosis
Source: Annals of Surgial Oncology, Nov 2008
Articles by Dr Laura Lambert, USA
CRS and Perioperative Intraperitoneal Chemotherapy for Colorectal Carcinomatosis:
Source: Annals of Surgical Oncology. 2007, Lambert, Laura A. and Paul F. Mansfield.
See: http://www.annalssurgicaloncology.org/cgi/content/full/14/11/3037
Articles by Dr Edward Levine, USA
CRS and HIPEC for the Treatment of Peritoneal Dissemination of Appendiceal and Colorectal Neoplasms
Source: Dr Edward Levine, ASCO 2008
“Appendiceal Carcinoma with Peritoneal Dissemination: Outcomes for the Best of the Best.”
Source: Annals of Surgical Oncology,2007, Dr Edward Levine, WFU
Survival Study for Pseudomyxoma Peritonei: DPAM, PMCA, PMCA 1
Source: Dr Edward Levine, American Journal of Surgical Pathology, May 2006
DPAM and HIPEC Treatment
Source: Wake Forest University
Articles by Dr Brian W Loggie, USA
CRS with HIPEC have improved quality and quantity of life for patients
Source:Dr Brian Loggie, 2007
Cox II expression in patients with Pseudomyxoma Peritonei and Disseminated Peritoneal Adenomucinosis
Source: Dr Brian Loggie
Articles referring to Dr Brian Loggie's patients
Source: PMP Pals' Network
Articles by Dr Andrew Lowy, USA
Minimally Invasive Laparoscopic Treatment of Pseudomyxoma Peritonei
Source: UCSD, Dr Andrew Lowy, 2009
Dr Andrew Lowy:Moores Cancer Center
Source: UCSD
Treatment of Pancreatic Cancer
Source: Dr Andrew Lowy UCSD
Articles by Dr Paul Mansfield, USA
Profile for Dr Paul Mansfield
Source: MD Anderson
CRS and HIPEC for the Treatment of Peritoneal Dissemination of Appendiceal and Colorectal Neoplasms
Source: Dr Paul Mansfield, ASCO 2008
CRS and Perioperative Intraperitoneal Chemotherapy for Colorectal Carcinomatosis:
Source: Annals of Surgical Oncology. 2007, Lambert, Laura A. and Paul F. Mansfield.
See: http://www.annalssurgicaloncology.org/cgi/content/full/14/11/3037
Laparoscopic Staging for Gastric Cancer
Source: Dr Paul Mansfield, MDACC, Annals of Surgical Oncology, 2001
Laparoscopy for Surgical Oncology
Source: MDACC
Articles by Dr Brendan J Moran, United Kingdom
CRS and HIPEC for the Treatment of Patients age 30-77 years
Source: North Hampshire Hospital, Basingstoke UK, 2007
Articles by Prof David L Morris, Australia
Radiofrequency Ablation for Treatment of Unresectable Colorectal Pulmonary Metastes
Radiofrequency ablation as an adjunct to systemic chemotherapy for colorectal pulmonary metastases. Radiofrequency ablation for colorectal pulmonary metastases represents a step forward towards a nonsurgical option of combining systemic and local treatment for metastatic disease and is a safe treatment with a low risk profile.
Source: David L. Morris, MD, PhD 2009
Morbidity and Mortality: Study of HIPEC and CRS for Treatment of Peritoneal Carcinomatosis
Source: Annals of Surgery, Feb 2009, Dr David Morris, Dr Tristan Yan
DPAM: Peritonectomy Improves Survival
Source Prof David L Morris, 2009
Assessment of risk factors following CRS and chemotherapy
Source: Dr David L Morris, Dr Tristan Yan, 2009Cost effectiveness of treatment with CRS and HIPEC
Source: Dr David L Morris, Dr Tristan Yan, Dec 2009
Pseudomyxoma Peritonei Long Term Survival (10 year study)
Source: Annals of Surgical Oncology, 2009, Prof David L Morris, St George Hospital,Univ of New South Wales, Sydney, NSW, AU
Long-term survival in patients with pseudomyxoma peritonei treated with cytoreductive surgery and perioperative intraperitoneal chemotherapy: 10 years of experience.
This report demonstrates long-term survival outcomes, acceptable perioperative outcomes, and a learning curve associated with the treatment of patients with pseudomyxoma peritonei.
In vivo model for Pseudomyxoma Peritonei research
Source: Prof David L Morris, Sydney Australia, 2009
Articles by Dr Stefaan Mulier, Belgium
Dr Stefaan Mulier provides HIPEC treatment for Pseudomyxoma Peritonei and Peritoneal Carcinomatosis
Source: Leopold Park Clinic in Brussels
Articles by Dr Herwart Mueller, Germany
CRS for Senior Patients
Source: Dr Herwart Mueller, Germany
Articles by Dr Garrett M Nash USA
Laparoscopic Surgery for the Treatment of Peritoneal Surface Malignancies including Pseudomyxoma Peritonei
Source: Memorial Sloan Kettering, NY
Articles by Dr Haydee Ojeda-Fournier, USA
Diagnostic Imaging of Pancreatic Cancer
Source: Dr Haydee Ojeda-Fournier, UCSD
Articles by Dr Gloria Ortega-Perez, Spain
Patient Selection for CRS and HIPEC
Source: Journal of Surgical Oncology 2009
Articles by Dr James Pingpank, USA
Peritoneal Carcinomatois Clinical Trials Study
Source: NIH, Dr James Pingpank, Feb 2009
Articles by Prof Pompiliu Piso, Germany
Peritoneal Carcinomatosis Treatment (Study) with Tumor Honing Peptides
Source: Dept of Radiology, Germany 2009
Peritoneal Carcinomatosis Prognosis following treatment with surgery and HIPEC
Source: Prof P Piso, 2009
CRS and HIPEC for the Treatment of Peritoneal Carcinomatosis
Source: Prof Pompiliu Piso, 3rd Annual Symposium, 2008
HIPEC Study with laboratory rats
Source: Deutscher Krebskongress, 2004
Articles by Dr B Ronnett, USA
CRS and HIPEC for the Treatment of Peritoneal Dissemination of Appendiceal and Colorectal Neoplasms
Source: Dr Edward Levine, ASCO 2008
DPAM Long Term Survival
Source: Dr BM Ronnett, Dr Paul H Sugarbaker, 2009
Articles by Dr Armando Sardi, USA
CRS and HIPEC offer longterm survival for Peritoneal Carcinomatosis of disseminated Appendiceal tumor origin
Source: Dr Armando Sardi, Mercy Med Center, Journal of American College of Surgeons, Sept 2009
Published abstracts by Dr Armando Sardi
Source: Mercy Medical Center
Steps to Prepare for SurgerySource: Mercy Medical Center
Curriculum Vitae for Dr Armando Sardi
Source: Mercy Medical Center
Profile for Dr Armando Sardi
Source: Mercy Medical Center
Articles by Dr Perry Shen, USA
Dr Perry Shen at WFU provides HIPEC
Source: Wake Forest University
Articles by Dr Paul H Sugarbaker, USA
Surgical Responsibilities in the Management of Peritoneal Carcinomatosis
Source: Dr Paul H Sugarbaker, June 2010, Pub Med
Mesenteric Cyst resulting in Pseudomyxoma Peritonei
Source: Dr Paul H Sugarbaker, 2010
Tailgut Cyst: An Unusual Case of Pseudomyxoma Peritonei
Source: Tumori, Dr Paul H Sugarbaker, 2009
Epithelial appendiceal neoplasms (abstract with availability to purchase article in full)
Source: The Cancer Journal, 2009
Epithelial appendiceal neoplasms: report reviews 900 cases treated at the Washington Hospital Center
Source: Dr Paul H Sugarbaker, Cancer Journal, May 2009
DPAM Long Term Survival
Source: Dr BM Ronnett, Dr Paul H Sugarbaker, 2009
Management of mucinous urachal neoplasm presenting as Pseudomyxoma Peritonei
Source: Dr Paul H Sugarbaker, 2008
Failure Analysis of Recurrent Disease Following CRS and IPC for Colorectal Cancer with Peritoneal Carcinomatosis
Source: Dr Paul H Sugarbaker, Dr Tristan Yan, 2007
Treatment of Peritoneal Surface Malignancy
Source: Dr Paul H Sugarbaker, Dr Tristan Yan, Journal of Transistional Medicine, 2006
Cytoreductive Surgery (includes graphic illustrations) Source: Dr Paul H Sugarbaker
Indications for use of CRS and HIPEC
Source: Dr Paul H Sugarbaker
Appendix Cancer Prognosis
Source: Dr Paul H Sugarbaker, Washington Hospital Center
Prognostic indicators for Peritoneal Carcinomatosis originating with gastrointestinal adenocarcinoma
Source: Dr Paul H Sugarbaker, 2005
Atlas of Appendix Cancer(includes graphic illustrations)
Source: Dr Paul H Sugarbaker
Articles referring to Dr Paul Sugarbaker and his patients
Source: PMP Pals' Network
Articles by Dr V J Verwaal,Holland
Population Based Study of Appendiceal Neoplasms and Pseudomyxoma Peritonei
Source: ESJO, 2008
Cytoreduction and HIPEC Treatment for Appendix Cancer and Pseudomyxoma Peritonei (pdf)
Source: Netherlands Cancer Institute, Prof VJ Verwaal, 2006
Articles by Dr Tristan Yan, Australia
Cost effectiveness of treatment with CRS and HIPEC
Source: Dr David L Morris, Dr Tristan Yan, Dec 2009
Morbidity and Mortality: Study of HIPEC and CRS for Treatment of Peritoneal Carcinomatosis
Source: Annals of Surgery, Feb 2009, Dr David Morris, Dr Tristan Yan
Assessment of risk factors following CRS and chemotherapy
Source: Dr David L Morris, Dr Tristan Yan, 2009
Failure Analysis of Recurrent Disease Following CRS and IPC for Colorectal Cancer with Peritoneal Carcinomatosis
Source: Dr Paul H Sugarbaker, Dr Tristan Yan, 2007
Treatment of Peritoneal Surface Malignancy
Source: Dr Paul H Sugarbaker, Dr Tristan Yan, Journal of Transistional Medicine, 2006
Articles by Dr H Zeh, USA
CRS and HIPEC for Treatment of Peritoneal Carcinomatosis in Colorectal Cancer Patient with Liver Metastasis: Study of 57 Patients
Source: Journal of Clinical Oncology 2008
CRS and HIPEC for Treatment of Peritoneal Carcinomatosis
Source: Annals of Surgical Oncology, 2008
CRS and HIPEC for Treatment of Colorectal Carcinomatosis
Source: Annals of Surgial Oncology, Nov 2008
Articles by Dr F Zoetmulder, Holland
Population Based Study of Appendiceal Neoplasms and Pseudomyxoma Peritonei
Source: ESJO, 2008
Prospective longitudinal study of quality of life following cytoreductive surgery and intraperitoneal chemotherapy for Pseudomyxoma Peritonei.
Submitted by Alves S, Mohamed F, Yadegarfar G, Youssef H, Moran BJ. Pseudomyxoma Peritonei Centre, Basingstoke and North Hampshire Hospital Foundation Trust, Aldermaston Road, Basingstoke, Hampshire RG24 9NA, UK.
Abstract
BACKGROUND: Pseudomyxoma peritonei (PMP) is characterized by mucinous ascites, predominantly arising form a perforated tumour of the appendix. This study aimed to assess Health-Related Quality of Life (HRQL) in patients following cytoreductive surgery and intraperitoneal chemotherapy for PMP.
METHODS: Over a one year period, 49 consecutive patients (13 male, 36 females) with a median age of 55 (range 37-81 years) were enrolled. Patients were asked to complete the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 questionnaire prior to surgery and at one, three, six and twelve months post-operatively.
RESULTS: 26 patients (53%) underwent complete cytoreduction and 20 (42%) patients had major tumour debulking. One patient died from progressive disease three months from surgery and two patients withdrew from the study within 6 months of surgery. Baseline questionnaire compliance was 100 per cent and remained high (overall 98% of eligible patients) during follow up. Grade III/IV morbidity occurred in 4 patients (9%). Patients undergoing both complete cytoreduction and major tumour debulking reported a clinically significant improvement in emotional well-being, appetite and global HRQL at 1 year following surgery.
CONCLUSION: Despite the high morbidity associated with cytoreductive surgery and intraperitoneal chemotherapy, an improvement in quality of life at 1 year following the procedure was seen following both complete cytoreduction and major tumour debulking. Longer term assessment is required to demonstrate the durability of this enhancement.
SOURCE: Eur J Surg Oncol. 2010 Sep 21.
Pseudomyxoma Peritonei Treatment Resources
How can I learn more about "PMP?"
Can I talk directly with other patients and their families?
To begin seeking resources for the treatment of Pseudomyxoma Peritonei, and related diseases, patients should obtain a copy of one's own pathology report to read how your particular case has been identified.
Join the PMP Pals' Network and begin communicating with other patients and their families today!
Updated 10.07.11
Questions to Ask Your Surgeon Prior to PMP Treatment
The PMP Pals’ Network suggests that patients prepare a personal list of questions prior to meeting ith a surgeon for a pre op evaluation.
Here are a few questions for your consideration. Refer to the PMP Pals’ Handbooks, Preparing for a Consultation with a Specialist and Preparing for Surgery for detailed lists of questions to ask your physician.
Treatment
Is my diagnosis aggressive? Does it require treatment?
What are my treatment options for my particular diagnosis?
If you were me, which option would you choose and why?
What is my prognosis with the treatment you recommend?
What is my prognosis without treatment?
What does “watch and wait” mean?
Surgery
Will any organs be removed?
If so, what, if any, are the ramifications of losing those organs?
Will I have an ostomy? If so, which type? Ileostomy? Colostomy? Urostomy?
If I have an ostomy, can it be “reversed?” If so, when?
Will I have the HIPEC treatment? Is HIPEC optional?
How will my pain be controlled after surgery?
What, if any, are the risks/complications from this surgery? From HIPEC?
Will the HIPEC treatment and your fees as my attending surgeon covered by my insurance?
Post Op (After Surgery)
Will my family caregiver be able to visit me in the ICU?
How often will you visit me during my hospitalization?
Who will oversee my post op recuperation? You (my attending surgeon) or the Fellows or Residents?
How long will I be hospitalized?
When will I be able to return to work?
When will I be able to return to work?
Surgeon’s Experience
How many patients with my diagnosis do you treat each year?
How many surgeries have you performed on patients with conditions like mine?
How often do you treat patients with the HIPEC procedure?
How experienced is your surgical team and post op nursing staff in treating patients with my condition?
Refer to the PMP Pals’ Handbooks, Preparing for a Consultation with a Specialist and Preparing for Surgery for detailed lists of questions to ask your physician.
Articles posted in PMP Pals, on the PMP Pals’ Network Blog are written from the perspective of patients and their family caregivers, and are not intended to substitute for licensed, professional legal or medical assistance. Patients should seek the guidance of their licensed healthcare professionals. Copyright © 2011 by Gabriella Graham/PMP Pals’ Network/All rights reserved.
This page has been donated by the family, friends and colleagues of Marcus Dwain Reynolds...
...therefore, please respect your fellow patients and caregivers by not copying or cutting and pasting any pages from this website onto yours.
The PMP Pals Network is a volunteer patient advocacy program. We support the services that we provide, including this web page, as volunteers and through subscriptions to our publications.
We neither solicit nor receive funds from pharmaceutical companies or healthcare providers, thus maintaining our dedication to serving as patient advocates.
Updated 10.07.11
The PMP Pals Network is a volunteer patient advocacy program. We support the services that we provide, including this web page, as volunteers and through subscriptions to our publications.
We neither solicit nor receive funds from pharmaceutical companies or healthcare providers, thus maintaining our dedication to serving as patient advocates.
Updated 10.07.11
